News | February 21, 2025
Wanbury reports 88% drop in Q3 FY25 PAT
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
the inspection conducted from January 27 to January 31, 2025
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
This rating reflects Lupin's leadership in environmental transparency and performance
No safety signals related to the vaccine candidate were identified
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Revenue up 11% to Rs 5,768 crore as compared to Rs 5,197 crore
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
Ipratropium Bromide Nasal Solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis
Subscribe To Our Newsletter & Stay Updated
